Ameriprise’s Unity Biotechnology UBX Stock Holding History

Ameriprise’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,817	Closed	-$105K	–	3739
2020 Q1	$105K	Sell	1,817 -1	-0.1%	-$63	﹤0.01%	3533
2019 Q4	$131K	Buy	+1,818	New	+$128K	﹤0.01%	3623

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's UBX Position: Q2 2020 in Review

Ameriprise sold out of Unity Biotechnology (UBX) in Q2 2020, closing a stake of 1,817 shares — an estimated $105K sold.

Ameriprise first reported a position in UBX in Q4 2019 and held it in 2 quarters. The position peaked at $131K in Q4 2019. 84 funds tracked by Wall St. Rank hold UBX as of Q2 2020.

Ameriprise reported no remaining Unity Biotechnology position as of Q2 2020 after selling out during the quarter.
Ameriprise sold 1,817 Unity Biotechnology shares in Q2 2020, an estimated $105K.
Ameriprise first reported a position in Unity Biotechnology in Q4 2019 and held it in 2 quarters.
Ameriprise's Unity Biotechnology position peaked at $131K in Q4 2019.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2020.

Based on Ameriprise's 13F filing for Q2 2020, filed 14 Aug 2020.